Form 4: IO Biotech Executive Acquires 140,000 Stock Options
SEC Form 4 Filing
Devin Whittemore Smith, General Counsel of IO Biotech, Inc., acquired 140,000 stock options on April 2, 2025.
Summary
- On April 2, 2025, Devin Whittemore Smith, the General Counsel of IO Biotech, Inc., acquired 140,000 stock options.
- The exercise price of these options is $1.07.
- One-fourth of the options vest on April 2, 2026, with the remainder vesting monthly over the following 36 months, contingent upon continued service.
- The options are subject to accelerated vesting under certain termination scenarios.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company executives.
Stakeholder Impact
- The acquisition of stock options by an executive can align their interests with those of shareholders, potentially incentivizing them to increase company value.
Key Dates
| Date | Description |
|---|---|
| 04/02/2025 | Date of transaction: Devin Whittemore Smith acquired 140,000 stock options. |
| 04/02/2026 | One-fourth of the acquired stock options vest. |
| 04/02/2035 | Expiration date of the stock options. |
| 04/04/2025 | Date of signature for the Form 4 filing. |
Keywords
IO Biotech, Stock Options, Form 4, Insider Trading, Executive Compensation, Beneficial Ownership, Securities Exchange Act, General Counsel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.